Overview

PF-06372865 in Subjects With Photosensitive Epilepsy

Status:
Completed
Trial end date:
2017-02-07
Target enrollment:
Participant gender:
Summary
PF-06372865 in subjects with photosensitive epilepsy
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Lorazepam
PF-06372865